Eosinophilic gastrointestinal disorders affect more than just the esophagus
Abstract
I n 1937, Dr R. Kaisjer provided the first description of eosinophilic gastroenteritis after reviewing surgical resections taken from various parts of the gastrointestinal (GI) tract (1). During the next few decades, other descriptions, again derived from whole tissue surgical specimens, followed. With the advent of flexible endoscopy in the 1960s, physicians were provided the necessary tools to procure mucosal biopsy samples from patients, escorting in a new era of defining the resident and pathological inflammatory cells of the intestinal mucosae. In the early 1980s, 2 publications identified eosinophils as markers of gastroesophageal reflux disease (2,3). The association of esophageal eosinophilia with gastroesophageal reflux disease held firm until the early 1990s when 3 publications provided the first descriptions of eosinophilic esophagitis (EoE) as a distinct disease entity (4,5,5a). Since then, 3 consensus recommendations and a European guideline have been published identifying and refining the diagnostic criteria for EoE (6–9). The emergence of EoE as an increasingly recognized distinct clinicopathological entity rekindled interest and raised questions about the role of the eosinophil in GI health and disease; for example, do eosinophils play a role in innate host defense and increase as a compensatory mechanism or is their increased presence a manifestation of a pathological inflammatory or allergic condition? (10,11). The latter explanation has certainly garnered…
Read the paper
Related studies
- Advantages and Disadvantages of Long-term Proton Pump Inhibitor Use
- Ivth brazilian consensus conference on helicobacter pylori infection
- A pSMAD/CDX2 complex is essential for the intestinalization of epithelial metaplasia
- S2k-Leitlinie Gastroösophageale Refluxkrankheit und eosinophile Ösophagitis der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – März 2023 – AWMF-Registernummer: 021–013
- Step-by-step management of refractory gastresophageal reflux disease
- Insights into Effects/Risks of Chronic Hypergastrinemia and Lifelong PPI Treatment in Man Based on Studies of Patients with Zollinger–Ellison Syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.